

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/124955/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Baker, Alexander T. , Mundy, Rosie, Davies, James , Rizkillah, Pierre T. and Parker, Alan L. 2019. Adenovirus serotype 26 utilises sialic acid bearing glycans as a primary cell entry receptor. [Online]. bioRxiv. Available at: <https://doi.org/10.1101/580076>

Publishers page: <https://doi.org/10.1101/580076>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



# 1 **Adenovirus serotype 26 utilises sialic acid bearing glycans as** 2 **a primary cell entry receptor**

3  
4 Alexander T. Baker<sup>1</sup>, Rosie Mundy<sup>1</sup>, James Davies<sup>1</sup>, Pierre J. Rizkallah<sup>2</sup>, Alan L Parker<sup>1</sup>.

5  
6 <sup>1</sup> Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park,  
7 Cardiff, CF14 4XN, UK.

8  
9 <sup>2</sup> Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park,  
10 Cardiff, CF14 4XN, UK.

## 11 12 13 **Correspondence:**

14 Dr Alan Parker  
15 Institute of Cancer and Genetics  
16 Cardiff University  
17 Heath Park  
18 Cardiff  
19 CF14 4XN  
20 Telephone: +44 2922 510 231  
21 Email: [ParkerAL@cardiff.ac.uk](mailto:ParkerAL@cardiff.ac.uk)  
22

23  
24 Running title: Ad26 binds sialic acid for cell entry.

25 Keywords: Adenovirus, sialic acid, receptor, crystal structure

26 Abstract word count: 150

27 Main text word count: 5009

28 Figure legend word count: 462

29 Supplemental figure legend word count: 404

30 Figure count: 5 + 4 supplementary + 1 supplementary table

31

32 **Abstract:**

33 Adenoviruses are clinically important agents. They cause respiratory distress, gastroenteritis, and  
34 epidemic keratoconjunctivitis (EKC). As non-enveloped, double stranded DNA viruses, they are easily  
35 manipulated, making them popular vectors for therapeutic applications, including vaccines. Species D  
36 adenovirus serotype 26 (HAdV-D26) is both a cause of EKC and other disease, and a promising vaccine  
37 vector. HAdV-D26 derived vaccines are under investigation as protective platforms against HIV, Zika,  
38 RSV infections and are in Phase-III clinical trials for Ebola.

39 We recently demonstrated that HAdV-D26 does not utilise CD46 or desmoglein 2 as entry receptors,  
40 whilst the putative interaction with Coxsackie and Adenovirus Receptor (CAR) is low affinity and  
41 unlikely to represent the primary cell receptor.

42 Here, we definitively establish sialic acid as the primary entry receptor utilised by HAdV-D26. We  
43 demonstrate removal of cell surface sialic acid inhibits HAdV-D26 infection and provide a high-  
44 resolution crystal structure of HAdV-D26 fiber-knob in complex with sialic acid.

45

## 46 **Introduction:**

47 Adenoviruses are clinically significant, both as human pathogens, and as platforms for therapeutic  
48 applications. As pathogens, human adenoviruses (HAdV) have been isolated from severe infections in  
49 both immunocompromised and healthy individuals(1, 2). Some adenoviruses have been associated  
50 with acute infection of the eye(3), respiratory(4, 5), and gastrointestinal tract(1, 6). In rare cases  
51 infections prove fatal, as observed in a recent neonatal infection of HAdV-D56(7), among adult  
52 patients in New Jersey with HAdV-B7d(8), and infamously with HAdV-E4 where large epidemics of  
53 adenovirus infection have been seen in military recruits(9, 10). However, most fatal infections are  
54 observed in immunocompromised individuals(11), such as those suffering from graft versus host  
55 disease (GVHD)(12) or HIV(13, 14).

56 Adenoviruses are classified into 7 species (A-G)(15), and between 57 and 90 serotypes depending on  
57 the taxonomic definitions used(16, 17). Some adenoviruses have been studied in detail, having well  
58 defined receptor tropisms, including as coxsackie and adenovirus receptor (CAR)(18, 19), CD46 (Major  
59 Complement Protein, MCP)(20–22), desmoglein 2 (DSG2)(23–25), or sialic acid bearing glycans(26–  
60 29). However, most serotypes have low seroprevalence in the population(30–33), though this varies  
61 significantly by geographical location(34, 35). Their rarity means many serotypes remain  
62 understudied, with poorly defined primary receptor interactions. This is especially true of the species  
63 D adenoviruses (HAdV-D); the largest of the adenoviral species, containing 35 of the 57 canonical  
64 serotypes(17).

65 Species D adenoviruses are associated with several pathogenicities. HAdV-D56 is a potentially fatal  
66 emergent respiratory pathogen comprised of a recombination between 4 species D adenoviruses(7).  
67 Opportunistic adenovirus infection isolated from HIV/AIDS patients are most commonly from species  
68 D, where they are associated with prolonged shedding in the gastrointestinal tract(13). HAdV-D has  
69 also been associated with genital disease(36, 37). The species D adenoviruses are best known,  
70 however, for causing epidemic keratoconjunctivitis (EKC) infections, which is endemic, but not isolated,  
71 to Japan(38, 39). Classically the primary EKC causing adenoviruses have been HAdV-D8(40–42), 37(42–  
72 44), and 64(42, 45) (previously classified as 19a(46)). More recently other species D adenovirus have  
73 been associated with EKC, including HAdV-D53(previously classified as HAdV-D22/H8)(47, 48), 54(49),  
74 56(50),

75 Their double stranded DNA genome makes them readily amenable to genetic modification(51), and  
76 therefore has made them attractive candidates for genetic manipulation for therapeutic applications  
77 in cancer (oncolytic viruses)(52) and as vaccine vectors(53, 54). Species D adenoviruses are of special  
78 interest as vaccine vectors. Their ability to induce robust cellular and humoral immunogenic responses

79 in humans, coupled with low seroprevalence rates in the general population(30, 33) makes them  
80 attractive platforms for vaccines, as evidenced by their progression through clinical trials for HIV(55,  
81 56), Zika(57), and Ebola treatment(58, 59). However, there remains a lack of understanding regarding  
82 their basic biology and mechanisms of cellular infection. This is exemplified by Adenovirus serotype  
83 26 (HAdV-D26), which is being investigated as a vaccine vector for zika(57), HIV(60), respiratory  
84 syncytial virus(61), and has entered phase III clinical trials as an Ebola vaccine(58).

85 Despite its clinical success, recent findings further highlight the lack of clarity over the primary  
86 receptor usage of HAdV-D26. It is now clear that, despite previous publications to the contrary, HAdV-  
87 D26 cannot engage CD46 as a primary cellular entry receptor(62). Instead, the HAdV-D26 fiber-knob  
88 protein (HAdV-D26K) may engage CAR as a primary receptor, although the affinity of this interaction  
89 is attenuated compared to the classical HAdV-C5 interaction with CAR due to the presence of an  
90 extended HAdV-D26 fiber-knob DG loop, which sterically inhibits the interaction with CAR(62). The  
91 deduced low affinity of the interaction between CAR and HAdV-D26 fiber-knob make it unlikely that  
92 CAR represents the definitive primary receptor of HAdV-D26.

93 Here, we conclusively demonstrate that HAdV-D26 utilises sialic acid bearing glycans as a primary  
94 entry receptor, and that this interaction can form a productive infection. We deduce the structure of  
95 HAdV-D26K in complex with sialic acid (Neu5Ac), demonstrating a similar topology to the known sialic  
96 acid interacting adenovirus HAdV-D37 fiber-knob in the sialic acid binding pocket, but highlight crucial  
97 mechanistic differences likely to enhance HAdV-D26 affinity for sialic acid compared to other  
98 serotypes.

## 99 **Results:**

### 100 **HAdV-D26K has an electrostatic profile permissive to sialic acid interaction:**

101 Our recent findings rule out any role for DSG-2 or CD46 in HAdV-D26 infection, whilst the low affinity  
102 of the interaction between HAdV-D26K and CAR made it an unlikely primary cell entry receptor.  
103 Previous amino acid sequence alignments demonstrated little conservation of sialic acid binding  
104 residues with the fiber-knob domains of the known sialic acid utilising adenoviruses HAdV-G52SFK  
105 (short fiber-knob) or Canine adenovirus serotype 2 (CAV-2)(62). However, these alignments indicated  
106 HAdV-D37, known to bind sialic acid in the apex of the fiber-knob, bore some similarity at a sequence  
107 level. We sought to evaluate the ability of HAdV-D26K to interact with the remaining previously  
108 described adenovirus receptor, sialic acid.

109 HAdV-D37 fiber-knob is identical to that of HAdV-D64, and highly homologous to HAdV-D8 (Fig.1A).  
110 These three viruses have been shown to cause epidemic keratoconjunctivitis (EKC) and to interact

111 with sialic acid. The closely related HAdV-D19p, differing from HAdV-D64 at only two residues, has  
112 also been shown to bind sialic acid, but does not cause EKC. We compared HAdV-D26K to these viruses  
113 to determine if a similar binding mechanism was possible.

114 These sialic acid binding viruses all have highly negative predicted isoelectric points (pI) (Fig.1A). We  
115 calculated the surface electrostatic potentials of these fiber-knob proteins, at pH7.35 to simulate the  
116 pH of extracellular fluid, using previously published crystal structures where available. There is no  
117 published structure of HAdV-D8K, so we generated a homology model based on the closest known  
118 relative with a crystal structure (Fig.1B).

119 The viruses are highly basic, with a concentration of positive charge in the central depression around  
120 the 3-fold axis corresponding to the previously reported sialic acid binding sites (Fig.1B-D). We  
121 observed that HAdV-D8 has the most basic surface potential (Fig.1B), followed by HAdV-D37/64  
122 (Fig.1C). HAdV-D19p is less basic, due to the two amino acid substitutions, compared to HAdV-D37/64,  
123 though the central depression is unaffected, as has previously been noted (Fig.1D)(63).

124 HAdV-D26K has a lower predicted pI, 6.49, and less positive surface potential (Fig.1A,E). However, the  
125 central depression of HAdV-D26K remains basic around the region where sialic acid is observed to  
126 bind in HAdV-D19p and HAdV-D37. HAdV-D26 retains the charge needed for sialic acid binding in the  
127 apex of the protein in the context of an otherwise acidic protein (Fig.1F).

#### 128 **HAdV-D26 requires cell surface sialic acid for efficient infection:**

129 Sequence alignment of HAdV-D26K with these known sialic acid utilising viruses, bearing a positively  
130 charged apex, showed conservation of key binding residues between serotypes (Fig.2A). We observe  
131 complete conservation of Tyr130, and Lys165 across the 4 serotypes, and conservation of Asp128 with  
132 HAdV-D8 (Fig.2A). Further, while Tyr135 is not conserved in HAdV-D26, inspection of the crystal  
133 structure of HAdV-D37K and HAdV-D19p in complex with sialic acid (PDB 1UXA and 1UXB,  
134 respectively)(63) reveals this to be a main chain oxygen contact, positioned similarly in HAdV-D26, and  
135 can be considered homologous.

136 To investigate the ability of HAdV-D26 to utilise sialic acid as a cell entry receptor we used a replication  
137 incompetent HAdV-C5 vector pseudotyped with the HAdV-D26 fiber-knob, expressing a GFP  
138 transgene. We performed infectivity studies in three cell lines, with and without pre-treatment with  
139 neuraminidase to remove cell surface sialic acid. The tested cell lines could be infected by the CD46  
140 (Fig.2B) or CAR (Fig.2C) mediated pathways to some extent, by HAdV-C5/B35K or HAdV-C5,  
141 respectively. However, infection via these routes was uninhibited by neuraminidase treatment.  
142 Transduction efficiency of HAdV-C5 and HAV-C5/B35K was actually enhanced by neuraminidase

143 treatment in some cases; an effect which has been previously observed(27, 64). This has been  
144 suggested to be due to a reduction in the electrostatic repulsion of the negatively charged capsid of  
145 HAdV-C5.

146 Infection by the HAdV-C5/D26K pseudotype was significantly reduced in all three cell lines following  
147 treatment with neuraminidase (Fig.2D). This inhibition is significant ( $P < 0.005$ ), resulting in >5-fold  
148 decrease in infection, in all three cell lines tested. These data indicate that HAdV-C5/D26K is likely to  
149 be utilising the sialic acid mediated pathway for infection, not CD46 or CAR.

### 150 **HAdV-D26 forms a stable complex with sialic acid:**

151 We crystallised HAdV-D26K in complex with sialic acid in order to clarify the mechanism of interaction.  
152 Refinement of structures generated from HAdV-D26K crystals soaked in sialic acid shows electron  
153 density for a small molecule ligand in the apical depression (Fig.3A), this is best described by a racemic  
154 mixture of  $\alpha$  and  $\beta$  anomers, in conjunction with double conformations of sialic acid (Fig.3B). The cubic  
155 space group (supplementary table 1) enabled assembly of the biological trimer. We observed three  
156 copies of sialic acid bound within the apex of the fiber-knob trimer (Fig.3C), as previously observed in  
157 HAdV-D37 and HAdV-D19p.

158 Sialic acid binding was observed in structures crystallised at both pH8.0 (PDB 6QU6) and pH4.0 (PDB  
159 6QU8). Observation of sialic acid density at high  $\sigma$ -values suggests a highly stable interaction  
160 (Supplementary Fig.1). Electron density demonstrates the C2 carboxyl and OH groups in two  
161 conformations, and the C6 glycerol group is flexible, with the C7-C8 bond rotating to alter the  
162 orientation of the glycerol arm relative to the pyranose ring and binding pocket (Fig.3A,B,  
163 Supplementary Fig.1). The glycerol group exhibits further flexibility at the C8-C9 bond, making the  
164 terminal oxygen mobile. The distribution of the density for the glycerol group is different at each pH  
165 (Supplementary Fig.1), suggesting pH could affect the preferred mode of interaction.

166 The most biologically relevant sialic acid conformation places the carboxyl group axial to the chair-  
167 conformation pyranose ring (Supplementary Fig.2), leaving the OH group pointing away from the fiber-  
168 knob and free to form an  $\alpha(2)$ -glycosidic bond as part of a glycan. This is suggestive of a terminal sialic  
169 acid residue, as the chain can extend out of the central depression, as was observed in the previously  
170 described HAdV-D37K:GD1a glycan structure(63, 65).

### 171 **HAdV-D26 possesses a sophisticated sialic acid binding pocket:**

172 Comparison between the HAdV-D26K and HAdV-D37K, the best described of the sialic acid binding  
173 adenoviruses, reveals several sialic acid contacts are conserved (Fig.4A,B). Lys349 and Tyr314 are  
174 identical, and while Lys349 exhibits some flexibility, all observed lysine conformations form a contact

175 with the carboxyl-group of the sialic acid (Supplementary Fig.3). Whilst Thr319 is not conserved in  
176 HAdV-D37 (which has a proline at this position), the main chain oxygen contact to the N-Acetyl  
177 nitrogen is spatially similar, so the bond can be considered homologous.

178 The HAdV-D26K sialic acid interface forms further contacts with sialic acid that are not observed in  
179 HAdV-D37K (Fig.4A, B). HAdV-D26K contacts the N-Acetyl oxygen of sialic acid using Asn312, which  
180 forms a polar contact and a water-bridge (Fig.4A). The comparable residue in HAdV-D37K, Thr310, is  
181 too short to form a direct polar interaction (Fig.4B), instead utilising a pair of water-bridges.

182 In HAdV-D37 the glycerol arm of sialic acid was only contacted by a water-bridge between Ser344 and  
183 the C7-OH. However, in HAdV-D26 all 3 OH groups in the glycerol arm form contacts. C7-OH is  
184 coordinated by water-bridges to both Asn312, and Gln348. C8-OH forms a water-bridge with Thr319,  
185 and C9-OH forms both a water-bridge and a polar contact directly to Gln348. Like Thr310, the serine  
186 belonging to HAdV-D37 at position 344 is too short to form a polar bond equivalent to the one with  
187 Gln348.

188 Notably, the density for the glycerol arm of sialic acid suggests several possible conformations  
189 (supplementary fig.2) which can be interpreted as flexibility. However, we suggest that, in HAdV-D26,  
190 this is unlikely since it is so well coordinated in all conformations observed, at both pH8.0 and pH4.0  
191 (supplementary fig.3). We propose that HAdV-D26K can form a stable interaction with the glycerol  
192 arm, regardless of the specific confirmation. The variable density can be explained as the average  
193 distribution (or partition) of the different discrete positions.

194 We also observe a hydrophobic interaction in HAdV-D26 with the N-Acetyl methyl group at C11  
195 (Fig.4C). A similar hydrophobic interaction is seen in HAdV-D37, where Tyr312 and Val322 form a  
196 hydrophobic patch (Fig.4D), but the HAdV-D37 interaction appears to be more selective, where Ile310,  
197 and Ile324 form a hydrophobic cradle around the methyl group (Fig.4C).

### 198 **HAdV-D26 binds sialic acid through an induced fit mechanism:**

199 We observe split density for Gln348 in both pH8.0 (Fig.5A) and pH4.0 (Fig.5B). Whilst conformation A  
200 can form polar contacts with sialic acid, conformation B points into the solvent and cannot. It is  
201 possible that Gln348 is flexible, but then is attracted to the charged density of the glycerol arm upon  
202 sialic acid interaction. We also observe greater occupancy of conformation A in the pH8.0 structure  
203 (approximately 0.7) while at pH4.0 the occupancy is evenly split. This suggests that the interaction  
204 may be more stable at higher pH, such as that associated with the pH found at the cell surface.

205 Ile324, which is seen to be involved in hydrophobic interactions with the N-Acetyl methyl group  
206 (Fig.4C), can also have multiple conformations. In an unliganded structure of HAdV-D26 fiber-knob

207 (PDB 6FJO) the long arm of Ile324 is seen to rotate (Fig.5C). However, in the ligated structure Ile324  
208 occupies a single conformation (Fig.5D) forming a cradle. This creates a larger hydrophobic patch and  
209 restricts the methyl group in space by pinching it between the pair of hydrophobic isoleucines,  
210 anchoring the N-Acetyl group.

## 211 **Discussion:**

212 Other adenoviruses have previously been shown to interact with sialic acid. These include CAV2(66),  
213 Turkey adenovirus 3 (TAdV-3)(67), and HAdV-G52 short fiber-knob(26, 68), but these viruses interact  
214 with sialic acid in lateral regions of the fiber-knob, dissimilar from HAdV-D26K. Four other human  
215 adenoviruses fiber-knob proteins (HAdV-D8/19p/37/64K) have been previously shown to utilise sialic  
216 acid, binding in the apical region. These viruses have high sequence similarity to each other, but not  
217 to HAdV-D26K, though they all share key sialic acid contact residues (Fig.1A,2A).

218 The structure of HAdV-D8 has not been determined, either alone or in complex with sialic acid, but  
219 infection by HAdV-D8 is sensitive to neuraminidase treatment suggesting sialic acid utilisation(69).  
220 Furthermore, HAdV-D8K has very high sequence homology and shared sialic acid contact residues with  
221 HAdV-D19p/37K making it logical to expect a similar interaction mechanism. In support of this we  
222 observe a similar electrostatic profile in the modelled fiber-knob as seen in HAdV-D37/64 (Fig.1B,C).  
223 HAdV-D64 has an identical fiber-knob domain to that of HAdV-D37, so fiber-knob interactions with  
224 sialic acid are likely to be conserved between these serotypes. HAdV-D26K conserves the key region  
225 of positive potential in the apical depression, but in the context of an otherwise more acidic protein  
226 (Fig.1E).

227 Inspection of the sialic binding pocket of HAdV-D26K reveals a much more complex mechanism of  
228 interaction than that previously reported for HAdV-D37K (Fig.4)(63). The overall topology of the  
229 pocket is similar, with hydrophobic residues around the N-Acetyl group and polar contacts between  
230 the carboxyl and C4-OH group. However, HAdV-D26K has several differences which increase the  
231 number of contacts between the sialic acid and the fiber-knob.

232 Subtle sequence changes enable more numerous interactions between HAdV-D26K and sialic acid  
233 than are possible in HAdV-D37K. In HAdV-D37 Pro317 forms a main chain oxygen contact to the  
234 nitrogen of sialic acid, however it also creates tension which rotates the N-terminal residue away from  
235 the carboxyl group of sialic acid. In HAdV-D26K, Tyr320, which is C-terminal of the Thr319 that is  
236 equivalent to Pro317 in HAdV-D37K does not create this tension and enables the main chain oxygen  
237 at position 320 to contact the sialic acid carboxyl group. Thr319, also forms a water-bridge with the  
238 C8-OH group, helping to stabilise the glycerol side-chain (Fig.4A).

239 This is one of several examples of HAdV-D26K being better evolved to contact sialic acid. The  
240 substitution of the Thr310 and Ser344 found in HAdV-D37K for longer charged residues (Asn312 and  
241 Gln348, respectively) in HAdV-D26K enables direct polar contacts, as well as additional water-bridge  
242 contacts. Substitution of Tyr308 and Val322 for more hydrophobic isoleucine residues in HAdV-D26  
243 (Ile 310 and Ile324, respectively) creates a hydrophobic indentation better tailored to fit around the  
244 N-Acetyl methyl group.

245 The high resolution of the datasets generated to determine the sialic acid bound HAdV-D26K structure  
246 enables visualisation of multiple residue conformations with partial occupancy. In unligated structures  
247 of HAdV-D26K (PDB 6FJO), Ile324 exhibits a double conformer, occupying the available space (Fig.5C).  
248 However, when sialic acid is bound, it is restricted to have a single conformation with the long arm  
249 facing away from the sialic acid site, towards the inter-monomer cleft. Ile310 has the opposite  
250 orientation and creates an indentation which cradles the methyl group of sialic acid. Tyr312 may  
251 further contribute to the hydrophobic cradle. Tyr312 would not normally be considered a hydrophobic  
252 residue, but the side chain oxygen faces towards the solvent, where it forms a polar interaction with  
253 the C4-OH on sialic acid (Fig.4A), leaving the face of the tyrosine ring exposed to the methyl group  
254 which may contribute hydrophobic character to the cradle. This tyrosine behaves in both a polar, and  
255 hydrophobic manner at the same time. We suggest that the long arm of Ile324 adopts the sialic acid  
256 binding conformation in response to the hydrophobic pressure exerted by sialic acid entering the  
257 pocket, minimising the exposed hydrophobic surface when unbound, holding the methyl group  
258 between the short arm of Ile310 and the Tyr312 ring, making this an example of induced fit.

259 The double occupancy of Gln348 may indicate a second induced fit mechanism. We observe two  
260 possible conformations of Gln348 (Fig.5C). While conformation A does not form any contacts,  
261 conformation B forms a polar bond, and water-bridge, with the sialic acid glycerol group. In HAdV-  
262 D37K the glycerol group forms only a water-bridge from C7-OH to Ser344, the spatial equivalent of  
263 Gln348. Whilst we have not determined the preferred conformation of the sialic acid glycerol group  
264 versus Gln348 conformation, we observed that it can form polar contacts with it regardless, while  
265 Gln348 is in conformation B (Fig.5C).

266 We suggest Gln348 may be labile until the binding of sialic acid. Upon sialic acid binding Gln348  
267 becomes attracted to the charged glycerol group causing it to stabilise in conformation A. This has the  
268 effect of “locking” the glycerol side chain in place, which is further restrained by water-bridge contacts  
269 to Thr319 and Asn312.

270 Gln348 has greater occupancy in a sialic acid binding conformation (conformation-A) at pH8.0, which  
271 corresponds more closely to the physiological conditions in which it would encounter at the cell

272 surface (Fig.5A). At pH4.0 Gln348 has approximately half occupancy in each conformation (Fig.5B).  
273 This implies the possibility of HAdV-D26K having lower sialic acid affinity under more acidic conditions,  
274 such as those encountered during endosomal trafficking down the lysosomal pathway.

275 Therefore, the HAdV-D26K binding pocket to sialic acid is summarised by three synchronous  
276 mechanisms. An N-Acetyl anchor comprised of a polar contact to Asn312 stabilised by a water bridge  
277 and an induced hydrophobic cradle around the methyl group. An inducible lock, where Gln348 forms  
278 a polar contact to the most terminal atoms in the glycerol arm, supported by a network of water  
279 bridges. Finally, a network of polar contacts to the carboxyl, C4 oxygen, and nitrogen atoms, which  
280 stabilise the pyranose ring.

281 This interaction in HAdV-D26K is a much more sophisticated binding mechanism compared to HAdV-  
282 D19p and the EKC causing viruses. However, the overall pocket topology and several key residues bear  
283 similarities. It may be surprising to observe such similarity given the low level of sequence homology  
284 HAdV-D26K has to the HAdV-D37K (56.76%, Fig.1A). Other regions, especially the loops, have highly  
285 dissimilar sequences. There is a precedent for this within adenovirus, with recombination events being  
286 reported in numerous settings(46, 47, 70, 71).

287 It has previously been suggested that many of the species D adenoviruses may have dual sialic acid  
288 binding affinity and CAR affinity(63). This has been observed in HAdV-D37/64, CAV-2(19, 66), and now  
289 HAdV-D26(62). Interestingly the species G adenovirus HAdV-G52 has also been observed to bind both  
290 CAR and sialic acid, but using two different fiber knob proteins on the same virus and a different  
291 mechanism of sialic acid interaction in the knob(26), which is shown to bind polysialic acid(29).  
292 Previous work has proposed CAR may be a receptor for many, if not all, of the species D adenoviruses  
293 with variable affinity(62, 63, 72), and suggest that sialic acid could also be widely utilised(63). These  
294 findings support that assertion, and adding another species D adenovirus, with low sequence  
295 similarity, to the pool of adenoviruses observed to bind both CAR and sialic acid.

296 Human adenovirus serotypes 43, 27, and 28 fiber-knobs share high sequence homology with HAdV-  
297 D26K, sharing the majority of the critical binding residues, and/or having structural homologues at  
298 those positions (Supplementary Fig.4). HAdV-D26K is the only species D adenovirus to have a  
299 glutamine at position 348 (HAdV-D26K numbering), though many have the shorter, but similarly  
300 charged, asparagine at this location, share the serine or similarly charged residue found in HAdV-D37K,  
301 or possess an asparagine which could behave similarly to glutamine. However, HAdV-D8 has an  
302 uncharged alanine at this position suggesting that a charged residue may not be strictly required for  
303 sialic acid binding, though may alter affinity (Supplementary Fig.4).

304 HAdV-D8K shares an asparagine at the same position as HAdV-D26K which we have shown to form  
305 polar and water-bridge contacts to sialic acid (Fig.4A). While this is unique among the classical EKC  
306 causing viruses HAdV-D19p/37/64, it is the most common residue at this position in the species D  
307 adenoviruses (Supplementary Fig.4).

308 The HAdV-D26K surface electrostatics are most like those of HAdV-D19pK. HAdV-D19pK is capable of  
309 binding sialic acid(63), and a limited effect is seen on infection of A549 cell binding after neuraminidase  
310 treatment to remove cell surface sialic acid(69). HAdV-D19p binding to Chang C (human conjunctival)  
311 cells was completely unaffected by neuraminidase treatment, though binding was very low regardless  
312 of neuraminidase treatment(27). This inability to bind Chang C cells was shown to depend upon a  
313 single lysine residue (Lys240) in the apex of the fiber-knob, but distant from the sialic binding pocket,  
314 creating a more acidic apical region in the lysine's absence(73). HAdV-D26K also lacks a lysine in this  
315 position and has the most acidic electrostatic profile observed in this study (Fig.1).

316 HAdV-D37K, and the identical HAdV-D64K, have been shown to preferentially interact with the sialic  
317 acid bearing GD1a glycan on the corneal cell surface, causing EKC(65). However, it seems unlikely that  
318 a protein capable of trivalent sialic acid binding is completely specific for GD1a, a di-sialylated glycan,  
319 given the wide range of available glycan motifs which are di- and tri-sialylated. The GD1a preference  
320 may be diminished in HAdV-D19p by the acidic surface caused by the two amino acid substitutions,  
321 creating a glycan preference for tissues outside of the eye. Similarly, HAdV-D26K may have a unique  
322 glycan preference, driving its tissue tropism towards cells with different glycosylation patterns.

323 These findings clarify the receptor tropism of HAdV-D26 and build upon the increasingly complex body  
324 of knowledge describing species D adenoviruses. The comparison of different sialic acid binding  
325 residues suggests greater plasticity regarding the specific residues needed for sialic acid binding than  
326 previously thought (Supplementary Fig.4). It seems highly likely that many adenoviruses in species D,  
327 and perhaps other species, may interact with sialic acid in this manner. This suggests potential causes  
328 of off target infection by species D derived viral vectors. Conversely, investigation of their specific  
329 glycan preferences may enable more tissue specific targeting. Knowledge of the sialic acid binding  
330 mechanism suggests mutations which may ablate sialic acid interaction, enabling engineering of  
331 better restricted tropisms for future virotherapies. This knowledge regarding HAdV-D26 receptor can  
332 inform clinical practice in the rare cases of acute HAdV-D26 infection, or in the face of adverse  
333 reactions to HAdV-D26 based vaccines, suggesting that sialic acid binding inhibitors, such as Zanamivir,  
334 or trivalent sialic acid derivatives(74) may make effective anti-HAdV-D26 therapies.

## 335 **Materials and Methods:**

### 336 **Infectivity assays:**

337 Cells were seeded at a density of 30,000 cells/well in a flat bottomed 96 well cell culture plate and  
338 incubated overnight at 37°C to adhere. Cells were washed twice with 200µl of PBS and 50ul of  
339 neuraminidase (Sigma-Aldrich, Cat#11080725001) was added to the appropriate wells at a  
340 concentration of 50mU/ml, diluted in serum free media, and incubated for 1hr at 37°C. Cells were  
341 cooled on ice and washed twice with 200µl of PBS. Green Fluorescent Protein (GFP) expressing,  
342 replication incompetent viruses were added to the appropriate wells at a concentration of 2000 or  
343 5000 viral particles per cell, in 100ul of serum free media, at 4°C, and incubated on ice for 1hr. Serum  
344 free media alone was added to uninfected control wells. Cells were washed twice with 200µl of cold  
345 PBS, complete media added (DMEM, 10% FCS) and incubated for 48hrs at 37°C. Cells were then  
346 trypsinised and transferred to a 96 well V-bottom plate, washed twice in 200µl of PBS and fixed in 2%  
347 paraformaldehyde for 20mins before wash, and resuspension in 200µl of PBS.

348 Samples were run in triplicate and analysed by flow cytometry on Attune NxT (ThermoFisher),  
349 analysed using FlowJo v10 (FlowJo, LLC), gating sequentially on singlets, cell population, and GFP  
350 positive cells. Levels of infection were defined as the percentage of GFP positive cells (%+ve), and/or  
351 Total Fluorescence (TF), defined as the percentage of GFP positive cells multiplied by the median  
352 fluorescent intensity (MFI) of the GFP positive population. These measures are distinct in that %+ve  
353 describes the total proportion of cells infected, and TF describes the total efficiency of transgene  
354 delivery.

### 355 **Amino Acid Sequence Alignments:**

356 Representative whole genomes of HAdV-D64, HAdV-D19p, HAdV-D26, and HAdV-D37 were selected  
357 from the National Center for Biotechnology Information (NCBI), the fiber-knob domain amino acid  
358 sequences were derived from them, defined as the translated nucleotide sequence of the fiber protein  
359 (pIV) from the conserved TLW hinge motif to the protein C-terminus. The fiber-knob domains were  
360 aligned using the EMBL-EBI Clustal Omega tool(75).

### 361 **Generation of Recombinant Fiber-Knob protein:**

362 SG13009 *E.coli* harbouring pREP-4 plasmid and pQE-30 expression vector containing the fiber-knob  
363 DNA sequence were cultured in 20ml LB broth with 100µg/ml ampicillin and 50µg/ml kanamycin  
364 overnight from glycerol stocks made in previous studies(76–78). 1L of TB (Terrific Broth, modified,  
365 Sigma-Aldrich) containing 100µg/ml ampicillin and 50µg/ml were inoculated with the overnight *E.coli*  
366 culture and incubated at 37°C until they reached OD0.6. IPTG was then added to a final concentration

367 of 0.5mM and the culture incubated at 37°C for 4hrs. Cells were then harvested by centrifugation at  
368 3000g, resuspended in lysis buffer (50mM Tris, pH8.0, 300mM NaCl, 1% (v/v) NP40, 1mg/ml Lysozyme,  
369 1mM  $\beta$ -mercaptoethanol), and incubated at room temperature for 30mins. Lysate was clarified by  
370 centrifugation at 30,000g for 30mins and filtered through a 0.22 $\mu$ m syringe filter (Millipore, Abingdon,  
371 UK). Clarified lysate was then loaded onto a 5ml HisTrap FF nickel affinity chromatography column  
372 (GE) at 2.0ml/min and washed with 5 column volumes into elution buffer A (50mM Tris [pH8.0],  
373 300mM NaCl, 1mM  $\beta$ -mercaptoethanol). Protein was eluted by 30min gradient elution from buffer A  
374 to B (buffer A + 400mM Imidazole). Fractions were analysed by reducing SDS-PAGE, and Fiber-knob  
375 containing fractions further purified using a superdex 200 10/300 size exclusion chromatography  
376 column (GE) in crystallisation buffer (10 mM Tris [pH 8.0] and 30 mM NaCl). Fractions were analysed  
377 by SDS-PAGE and pure fractions concentrated by centrifugation in Vivaspin 10,000 MWCO (Sartorius,  
378 Goettingen, Germany) proceeding crystallisation.

### 379 **Crystallisation and structure determination.**

380 Protein samples were purified into crystallisation buffer (10 mM TRIS [pH 8.0] and 30 mM NaCl). The  
381 final protein concentration was approximately 10 mg/ml. Commercial crystallisation screen solutions  
382 were dispensed into 96-well plates using an Art-Robbins Instruments Griffon dispensing robot (Alpha  
383 Biotech, Ltd), in sitting-drop vapour-diffusion format. Drops containing 200nl of screen solution and  
384 200nl of protein solution were equilibrated against a reservoir of 60 $\mu$ l crystallisation solution. The  
385 plates were sealed and incubated at 18°C.

386 Crystals of HAdV-D26K appeared in PACT Premier condition B01 and B04 (0.1 M MIB [Malonic acid,  
387 Imidazole, Boric acid], 25 % w/v PEG 1500, pH4.0 and pH8.0 respectively), within 1 to 7 days. Crystals  
388 were then soaked in reservoir solution containing N-Acetylneuraminic acid (Neu5Ac, Sigma-Aldrich  
389 Cat#A2388) at a final concentration of 10mM and incubated overnight prior to harvest. Crystals were  
390 cryoprotected with reservoir solution to which ethylene glycol was added at a final concentration of  
391 25%. Crystals were harvested in thin plastic loops and stored in liquid nitrogen for transfer to the  
392 synchrotron. Data were collected at Diamond Light Source beamline I04, running at a wavelength of  
393 0.9795Å. During data collection, crystals were maintained in a cold air stream at 100°K. Dectris Pilatus  
394 6M detectors recorded the diffraction patterns, which were analysed and reduced with XDS(79), Xia2,  
395 DIALS(80), and Autoproc(81). Scaling and merging data was completed with Pointless, Aimless and  
396 Truncate from the CCP4 package(82). Structures were solved with PHASER, COOT was used to correct  
397 the sequences and adjust the models, REFMAC5 was used to refine the structures and calculate maps.  
398 Graphical representations were prepared with PyMOL(83). Reflection data and final models were

399 deposited in the PDB database with accession codes: 6QU6, 6QU8, and 6FJO. Full crystallographic  
400 refinement statistics are given in Supplementary Table 1

#### 401 **Calculation of electrostatic surface potentials and isoelectric points:**

402 HAdV-D37, HAdV-D19p, and HAdV-D26 used PDB IUXA, PDB 1UXB, and PDB 6QU8, respectively, as the  
403 input. HAdV-D8 was calculated using a homology model, generated as described below, for input.

404 The PDB2PQR server (V 2.1.1)(84) was used assign charge and radius parameters using the PARSE  
405 forcefield, and assigned protonation states using PROPKA, at pH7.35. APBS(85) was used to calculate  
406 electrostatic surface potentials, and the map output was visualised in PyMol(83).

#### 407 **Homology modelling of Adenovirus serotype 8**

408 The I-TASSER protein structure and function prediction server(86–88) was used to generate a  
409 homology model of HAdV-D8 based on the published sequence of HAdV-D8(42), using the published  
410 structure of it's closest relative (by sequence identity), HAdV-D19p(63). The resultant monomer was  
411 then copied three times, using the HAdV-19p trimer as a template, and the monomers aligned in  
412 PyMol(83) so as to generate a model of the complete HAdV-D8K trimer.

#### 413 **Acknowledgements**

414 A.T.B is supported by a Tenovus Cancer Care PhD studentship to A.L.P (project reference  
415 PhD2015/L13). J. A. D is supported by a Cancer Research UK Biotherapeutics Drug Discovery Project  
416 Award to A.L.P. (project reference C52915/A23946). A.L.P and P.R are funded by Higher Education  
417 Funding Council for Wales.

418 The authors wish to acknowledge the Diamond Light Source for beamtime (proposal mx14843), and  
419 the staff of beamline I04 for assistance with diffraction data collection.

- 420 1. T. Lion, Adenovirus Infections in Immunocompetent and Immunocompromised Patients. *Clin.*  
421 *Microbiol. Rev.* **27**, 441–462 (2014).
- 422 2. Adenovirus Clinical Presentation: History, Physical, Complications, (available at  
423 <https://emedicine.medscape.com/article/211738-clinical>).
- 424 3. D. Garcia-Zalisnak, C. Rapuano, J. D. Sheppard, A. R. Davis, Adenovirus Ocular Infections:  
425 Prevalence, Pathology, Pitfalls, and Practical Pointers. *Eye Contact Lens.* **44 Suppl 1**, S1–S7  
426 (2018).
- 427 4. R. Civljak *et al.*, Viral pathogens associated with acute respiratory illness in hospitalized adults  
428 and elderly from Zagreb, Croatia, 2016 to 2018. *J. Med. Virol.* (2019), doi:10.1002/jmv.25437.
- 429 5. C. A. Pfortmueller *et al.*, Severe acute respiratory distress syndrome (ARDS) induced by human  
430 adenovirus B21: Report on 2 cases and literature review. *J. Crit. Care.* **51**, 99–104 (2019).
- 431 6. K. Kosulin *et al.*, *Clin. Microbiol. Infect.*, in press, doi:10.1016/j.cmi.2015.12.013.
- 432 7. C. M. Robinson *et al.*, Computational analysis and identification of an emergent human  
433 adenovirus pathogen implicated in a respiratory fatality. *Virology.* **409**, 141–147 (2011).
- 434 8. M. E. Killerby *et al.*, Respiratory Illness Associated With Emergent Human Adenovirus Genome  
435 Type 7d, New Jersey, 2016-2017. *Open Forum Infect. Dis.* **6**, ofz017 (2019).
- 436 9. R. N. Potter, J. A. Cantrell, C. T. Mallak, J. C. Gaydos, Adenovirus-associated Deaths in US Military  
437 during Postvaccination Period, 1999–2010. *Emerg. Infect. Dis.* **18**, 507–509 (2012).
- 438 10. S. A. Kolavic-Gray *et al.*, Large Epidemic of Adenovirus Type 4 Infection among Military Trainees:  
439 Epidemiological, Clinical, and Laboratory Studies. *Clin. Infect. Dis.* **35**, 808–818 (2002).
- 440 11. S. Khanal, P. Ghimire, A. S. Dhamoon, The Repertoire of Adenovirus in Human Disease: The  
441 Innocuous to the Deadly. *Biomedicines.* **6**, 30 (2018).
- 442 12. S. H. Norris, T. C. Butler, N. Glass, R. Tran, Fatal Hepatic Necrosis Caused by Disseminated Type  
443 5 Adenovirus Infection in a Renal Transplant Recipient. *Am. J. Nephrol.* **9**, 101–105 (1989).
- 444 13. Y. M. A. Al Qurashi, M. A. Alkhalaf, L. Lim, M. Guiver, R. J. Cooper, Sequencing and phylogenetic  
445 analysis of the hexon, fiber, and penton regions of adenoviruses isolated from AIDS patients. *J.*  
446 *Med. Virol.* **84**, 1157–1165 (2012).
- 447 14. J. C. Hierholzer, Adenoviruses in the immunocompromised host. *Clin. Microbiol. Rev.* **5**, 262–274  
448 (1992).
- 449 15. A. M. Q. King, M. J. Adams, E. B. Carstens, E. J. Lefkowitz, Eds., in *Virus Taxonomy* (Elsevier, San  
450 Diego, 2012; <http://www.sciencedirect.com/science/article/pii/B9780123846846000094>), pp.  
451 125–141.
- 452 16. International Committee on Taxonomy of Viruses, *Virus taxonomy: classification and*  
453 *nomenclature of viruses : sixth report of the International Committee on Taxonomy of Viruses*  
454 (Springer-Verlag, Wien ; New York, 1995), *Archives of virology. Supplementum ; 10*.
- 455 17. HAdV Working Group, <http://hadvwg.gmu.edu/>, (available at <http://hadvwg.gmu.edu/>).

- 456 18. J. M. Bergelson *et al.*, Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses  
457 2 and 5. *Science*. **275**, 1320–1323 (1997).
- 458 19. E. Seiradake, H. Lortat-Jacob, O. Billet, E. J. Kremer, S. Cusack, Structural and Mutational Analysis  
459 of Human Ad37 and Canine Adenovirus 2 Fiber Heads in Complex with the D1 Domain of  
460 Coxsackie and Adenovirus Receptor. *J. Biol. Chem.* **281**, 33704–33716 (2006).
- 461 20. A. Gaggar, D. M. Shayakhmetov, A. Lieber, CD46 is a cellular receptor for group B adenoviruses.  
462 *Nat. Med.* **9**, 1408–1412 (2003).
- 463 21. C. Fleischli *et al.*, Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on  
464 the membrane cofactor protein CD46 receptor. *J. Gen. Virol.* **88**, 2925–2934 (2007).
- 465 22. M. Marttila *et al.*, CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7.  
466 *J. Virol.* **79**, 14429–14436 (2005).
- 467 23. H. Wang *et al.*, Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. *Nat. Med.*  
468 **17**, 96–104 (2011).
- 469 24. E. Vassal-Stermann *et al.*, Mapping of Adenovirus of serotype 3 fibre interaction to desmoglein  
470 2 revealed a novel ‘non-classical’ mechanism of viral receptor engagement. *Sci. Rep.* **8** (2018),  
471 doi:10.1038/s41598-018-26871-x.
- 472 25. E. Vassal-Stermann *et al.*, Cryo-EM structure of adenovirus type 3 fibre with desmoglein 2 shows  
473 a novel mode of receptor engagement. *bioRxiv*, 471383 (2018).
- 474 26. A. Lenman *et al.*, Human Adenovirus 52 Uses Sialic Acid-containing Glycoproteins and the  
475 Coxsackie and Adenovirus Receptor for Binding to Target Cells. *PLOS Pathog.* **11**, e1004657  
476 (2015).
- 477 27. N. Arnberg, P. Pring-Åkerblom, G. Wadell, Adenovirus Type 37 Uses Sialic Acid as a Cellular  
478 Receptor on Chang C Cells. *J. Virol.* **76**, 8834–8841 (2002).
- 479 28. N. Arnberg, K. Edlund, A. H. Kidd, G. Wadell, Adenovirus Type 37 Uses Sialic Acid as a Cellular  
480 Receptor. *J. Virol.* **74**, 42–48 (2000).
- 481 29. A. Lenman *et al.*, Polysialic acid is a cellular receptor for human adenovirus 52. *Proc. Natl. Acad.*  
482 *Sci.*, 201716900 (2018).
- 483 30. P. Abbink *et al.*, Comparative Seroprevalence and Immunogenicity of Six Rare Serotype  
484 Recombinant Adenovirus Vaccine Vectors from Subgroups B and D. *J. Virol.* **81**, 4654–4663  
485 (2007).
- 486 31. M. Aste-Amézaga *et al.*, Quantitative adenovirus neutralization assays based on the secreted  
487 alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of  
488 adenovector vaccines. *Hum. Gene Ther.* **15**, 293–304 (2004).
- 489 32. S. J. Moyo *et al.*, Prevalence and molecular characterisation of human adenovirus in diarrhoeic  
490 children in Tanzania; a case control study. *BMC Infect. Dis.* **14**, 666 (2014).
- 491 33. A. R. Thorner *et al.*, Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in  
492 Individuals from Sub-Saharan Africa. *J. Clin. Microbiol.* **44**, 3781–3783 (2006).

- 493 34. M. Pauly *et al.*, High prevalence and diversity of species D adenoviruses (HAdV-D) in human  
494 populations of four Sub-Saharan countries. *Viol. J.* **11**, 25 (2014).
- 495 35. R. S. Dakin, A. L. Parker, C. Delles, S. A. Nicklin, A. H. Baker, Efficient transduction of primary  
496 vascular cells by the rare adenovirus serotype 49 vector. *Hum. Gene Ther.* **26**, 312–319 (2015).
- 497 36. P. A. Phillips, G. B. Harnett, M. M. Gollow, Adenovirus type 19 and a closely related new serotype  
498 in genital infection. *Br. J. Vener. Dis.* **58**, 131–132 (1982).
- 499 37. P. D. Swenson, M. S. Lowens, C. L. Celum, J. C. Hierholzer, Adenovirus types 2, 8, and 37  
500 associated with genital infections in patients attending a sexually transmitted disease clinic. *J.*  
501 *Clin. Microbiol.* **33**, 2728–2731 (1995).
- 502 38. K. Aoki, Y. Tagawa, A Twenty-One Year Surveillance of Adenoviral Conjunctivitis in Sapporo,  
503 Japan. *Int. Ophthalmol. Clin.* **42**, 49–54 (2002).
- 504 39. P. R. Kinchington, E. G. Romanowski, Y. Jerold Gordon, Prospects for adenovirus antivirals. *J.*  
505 *Antimicrob. Chemother.* **55**, 424–429 (2005).
- 506 40. Z. Lei *et al.*, Outbreaks of epidemic keratoconjunctivitis caused by human adenovirus type 8 in  
507 the Tibet Autonomous Region of China in 2016. *PLoS ONE.* **12** (2017),  
508 doi:10.1371/journal.pone.0185048.
- 509 41. E. Hage *et al.*, Molecular phylogeny of a novel human adenovirus type 8 strain causing a  
510 prolonged, multi-state keratoconjunctivitis epidemic in Germany. *Sci. Rep.* **7** (2017),  
511 doi:10.1038/srep40680.
- 512 42. H. Kaneko *et al.*, Analysis of the complete genome sequence of epidemic keratoconjunctivitis-  
513 related human adenovirus type 8, 19, 37 and a novel serotype. *J. Gen. Virol.* **90**, 1471–1476  
514 (2009).
- 515 43. J. C. de Jong *et al.*, Adenovirus 37: identification and characterization of a medically important  
516 new adenovirus type of subgroup D. *J. Med. Virol.* **7**, 105–118 (1981).
- 517 44. T. Ariga *et al.*, Five New Genome Types of Adenovirus Type 37 Caused Epidemic  
518 Keratoconjunctivitis in Sapporo, Japan, for More Than 10 Years. *J. Clin. Microbiol.* **43**, 726–732  
519 (2005).
- 520 45. C. M. Robinson *et al.*, Human adenovirus type 19: genomic and bioinformatics analysis of a  
521 keratoconjunctivitis isolate. *Virus Res.* **139**, 122–126 (2009).
- 522 46. X. Zhou *et al.*, Analysis of human adenovirus type 19 associated with epidemic  
523 keratoconjunctivitis and its reclassification as adenovirus type 64. *Invest. Ophthalmol. Vis. Sci.*  
524 **53**, 2804–2811 (2012).
- 525 47. M. P. Walsh *et al.*, Evidence of Molecular Evolution Driven by Recombination Events Influencing  
526 Tropism in a Novel Human Adenovirus that Causes Epidemic Keratoconjunctivitis. *PLOS ONE.* **4**,  
527 e5635 (2009).
- 528 48. K. Aoki, N. Kitaichi, R. Hinokuma, S. Ohno, Characteristics of Epidemic Keratoconjunctivitis due  
529 to Novel Adenovirus Types. **1**, 3 (2017).

- 530 49. K. Matsuura *et al.*, Human adenoviral type 54 keratoconjunctivitis accompanied by stellate  
531 keratitis and keratic precipitates: two cases. *BMC Ophthalmol.* **19**, 7 (2019).
- 532 50. G. Huang *et al.*, Outbreak of Epidemic Keratoconjunctivitis Caused by Human Adenovirus Type  
533 56, China, 2012. *PLOS ONE.* **9**, e110781 (2014).
- 534 51. R. J. Stanton, B. P. McSharry, M. Armstrong, P. Tomasec, G. W. G. Wilkinson, Re-engineering  
535 adenovirus vector systems to enable high-throughput analyses of gene function. *BioTechniques.*  
536 **45**, 659–662, 664–668 (2008).
- 537 52. H. Uusi-Kerttula, S. Hulin-Curtis, J. Davies, A. L. Parker, Oncolytic Adenovirus: Strategies and  
538 Insights for Vector Design and Immuno-Oncolytic Applications. *Viruses.* **7**, 6009–6042 (2015).
- 539 53. D. Majhen *et al.*, Adenovirus-Based Vaccines for Fighting Infectious Diseases and Cancer:  
540 Progress in the Field. *Hum. Gene Ther.* **25**, 301–317 (2014).
- 541 54. H. Chen *et al.*, Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of  
542 Adenoviridae. *J. Virol.* **84**, 10522–10532 (2010).
- 543 55. D. H. Barouch *et al.*, Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-  
544 blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-  
545 19). *The Lancet.* **392**, 232–243 (2018).
- 546 56. L. R. Baden *et al.*, First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing  
547 HIV-1 Env (IPCAVD 002). *J. Infect. Dis.* **210**, 1052–1061 (2014).
- 548 57. F. Cox *et al.*, Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral  
549 and cellular immune responses and protects mice and nonhuman primates against ZIKV  
550 challenge. *PLOS ONE.* **13**, e0202820 (2018).
- 551 58. Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines  
552 Ad26.ZEBOV and/or MVA-BN-Filo - Full Text View - ClinicalTrials.gov, (available at  
553 [https://clinicaltrials.gov/ct2/show/NCT02661464?term=adenovirus&recrs=a&cond=ebola&ran](https://clinicaltrials.gov/ct2/show/NCT02661464?term=adenovirus&recrs=a&cond=ebola&rank=1)  
554 [k=1](https://clinicaltrials.gov/ct2/show/NCT02661464?term=adenovirus&recrs=a&cond=ebola&rank=1)).
- 555 59. T. W. Geisbert *et al.*, Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors  
556 Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge. *J. Virol.*  
557 **85**, 4222–4233 (2011).
- 558 60. Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vected HIV-1 Vaccine - Full  
559 Text View - ClinicalTrials.gov, (available at <https://clinicaltrials.gov/ct2/show/NCT02366013>).
- 560 61. A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F  
561 Protein (Ad26.RSV.preF) Vaccine in Adults - Full Text View - ClinicalTrials.gov, (available at  
562 <https://clinicaltrials.gov/ct2/show/NCT03795441>).
- 563 62. A. T. Baker *et al.*, Diversity within the adenovirus fiber knob hypervariable loops influences  
564 primary receptor interactions. *bioRxiv*, 406819 (2018).
- 565 63. W. P. Burmeister, D. Guilligay, S. Cusack, G. Wadell, N. Arnberg, Crystal Structure of Species D  
566 Adenovirus Fiber Knobs and Their Sialic Acid Binding Sites. *J. Virol.* **78**, 7727–7736 (2004).

- 567 64. S. M. Arcasoy *et al.*, MUC1 and Other Sialoglycoconjugates Inhibit Adenovirus-mediated Gene  
568 Transfer to Epithelial Cells. *Am. J. Respir. Cell Mol. Biol.* **17**, 422–435 (1997).
- 569 65. E. C. Nilsson *et al.*, The GD1a glycan is a cellular receptor for adenoviruses causing epidemic  
570 keratoconjunctivitis. *Nat. Med.* **17**, 105–109 (2011).
- 571 66. E. Seiradake *et al.*, The cell adhesion molecule “CAR” and sialic acid on human erythrocytes  
572 influence adenovirus in vivo biodistribution. *PLoS Pathog.* **5**, e1000277 (2009).
- 573 67. A. K. Singh *et al.*, Structure and Sialyllactose Binding of the Carboxy-Terminal Head Domain of  
574 the Fibre from a Siadenovirus, Turkey Adenovirus 3. *PLoS One.* **10**, e0139339 (2015).
- 575 68. M.-C. Amoureux *et al.*, Polysialic Acid Neural Cell Adhesion Molecule (PSA-NCAM) is an adverse  
576 prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. *BMC Cancer.*  
577 **10**, 91 (2010).
- 578 69. N. Arnberg, A. H. Kidd, K. Edlund, F. Olfat, G. Wadell, Initial Interactions of Subgenus D  
579 Adenoviruses with A549 Cellular Receptors: Sialic Acid versus  $\alpha$ VIntegrins. *J. Virol.* **74**, 7691–7693  
580 (2000).
- 581 70. C. M. Robinson *et al.*, Molecular evolution of human adenoviruses. *Sci. Rep.* **3**, 1812 (2013).
- 582 71. A. N. Lukashev, O. E. Ivanova, T. P. Eremeeva, R. D. Iggo, Evidence of frequent recombination  
583 among human adenoviruses. *J. Gen. Virol.* **89**, 380–388 (2008).
- 584 72. I. Kirby *et al.*, Adenovirus Type 9 Fiber Knob Binds to the Coxsackie B Virus-Adenovirus Receptor  
585 (CAR) with Lower Affinity than Fiber Knobs of Other CAR-Binding Adenovirus Serotypes. *J. Virol.*  
586 **75**, 7210–7214 (2001).
- 587 73. S. Huang, V. Reddy, N. Dasgupta, G. R. Nemerow, A Single Amino Acid in the Adenovirus Type 37  
588 Fiber Confers Binding to Human Conjunctival Cells. *J. Virol.* **73**, 2798–2802 (1999).
- 589 74. S. Spjut *et al.*, A Potent Trivalent Sialic Acid Inhibitor of Adenovirus Type 37 Infection of Human  
590 Corneal Cells. *Angew. Chem. Int. Ed.* **50**, 6519–6521 (2011).
- 591 75. F. Sievers *et al.*, Fast, scalable generation of high-quality protein multiple sequence alignments  
592 using Clustal Omega. *Mol. Syst. Biol.* **7**, 539–539 (2011).
- 593 76. L. Coughlan *et al.*, Retargeting Adenovirus Serotype 48 Fiber Knob Domain by Peptide  
594 Incorporation. *Hum. Gene Ther.* **25**, 385–394 (2014).
- 595 77. H. Uusi-Kerttula *et al.*, Pseudotyped  $\alpha$ v $\beta$ 6 integrin-targeted adenovirus vectors for ovarian  
596 cancer therapies. *Oncotarget.* **7**, 27926–27937 (2016).
- 597 78. L. Coughlan *et al.*, In Vivo Retargeting of Adenovirus Type 5 to  $\alpha$ v $\beta$ 6 Integrin Results in Reduced  
598 Hepatotoxicity and Improved Tumor Uptake following Systemic Delivery. *J. Virol.* **83**, 6416–6428  
599 (2009).
- 600 79. W. Kabsch, XDS. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 125–132 (2010).
- 601 80. G. Winter *et al.*, DIALS: implementation and evaluation of a new integration package. *Acta*  
602 *Crystallogr. Sect. Struct. Biol.* **74**, 85–97 (2018).

- 603 81. C. Vonrhein *et al.*, Data processing and analysis with the autoPROC toolbox. *Acta Crystallogr. D*  
604 *Biol. Crystallogr.* **67**, 293–302 (2011).
- 605 82. E. J. Dodson, M. Winn, A. Ralph, in *Methods in Enzymology* (Academic Press, 1997;  
606 <http://www.sciencedirect.com/science/article/pii/S0076687997770344>), vol. 277 of  
607 *Macromolecular Crystallography Part B*, pp. 620–633.
- 608 83. Schrödinger, LLC., The PyMOL Molecular Graphics System, Version 2.0.
- 609 84. T. J. Dolinsky, J. E. Nielsen, J. A. McCammon, N. A. Baker, PDB2PQR: an automated pipeline for  
610 the setup of Poisson-Boltzmann electrostatics calculations. *Nucleic Acids Res.* **32**, W665-667  
611 (2004).
- 612 85. N. A. Baker, D. Sept, S. Joseph, M. J. Holst, J. A. McCammon, Electrostatics of nanosystems:  
613 application to microtubules and the ribosome. *Proc. Natl. Acad. Sci. U. S. A.* **98**, 10037–10041  
614 (2001).
- 615 86. A. Roy, A. Kucukural, Y. Zhang, I-TASSER: a unified platform for automated protein structure and  
616 function prediction. *Nat. Protoc.* **5**, 725–738 (2010).
- 617 87. J. Yang *et al.*, The I-TASSER Suite: protein structure and function prediction. *Nat. Methods.* **12**,  
618 7–8 (2015).
- 619 88. Y. Zhang, I-TASSER server for protein 3D structure prediction. *BMC Bioinformatics.* **9**, 40 (2008).
- 620

621 **Figure 1: HAdV-D26K forms a local basic area in the apical depression to facilitate sialic acid binding**  
622 **despite net positive surface potential.** HAdV-D26K has low (56.76%) sequence identity with fiber-  
623 knobs known to bind sialic acid by a similar mechanism, and an acidic isoelectric point (A). The  
624 electrostatic potential surfaces of HAdV-D8K (B), HAdV-D64/37 (C), and HAdV-D19p (D) fiber-knobs  
625 are highly basic, especially about the central depression about the 3-fold axis. HAdV-D26 fiber-knob is  
626 less basic overall but maintains positive potential in the central depression (E). Surfaces are displayed  
627 at  $\pm 10\text{mV}$ .

628 **Figure 2: HAdV-D26K shares key binding residues with sialic acid utilising adenoviruses and exploits**  
629 **sialic acid to infect cells.** Sequence alignment of HAdV-D26K shows conservation of key binding  
630 residues with known sialic acid binding adenoviruses (A). Residues highlighted in Red form polar  
631 contacts with sialic acid, green contact sialic acid via water-bridge, a black underline indicates both  
632 direct and water-bridge contacts, blue indicates hydrophobic contacts. Neuraminidase treatment  
633 does not reduce the ability of HAdV-D5/B35K (B) or HAdV-C5 (C) to infect SKOV-3 (ovarian  
634 adenocarcinoma), BT-20 (breast carcinoma), or MDA-231 (metastatic breast adenocarcinoma) cells,  
635 while HAdV-D5/D26K (D) is significantly inhibited.  $n=3$  biological replicates, error =  $\pm\text{SD}$ .

636 **Figure 3: Sialic acid binds in the apical depression of adenovirus 26 fiber-knob protein.** Sialic acid  
637 (orange) is seen to bind in 3 locations in the apical depression of the HAdV-D26 fiber-knob, bridging  
638 between monomers (shades of blue) of the trimeric assembly (A). The map shows clear density for a  
639 ligand (B), which is best described by a double conformer of sialic acid (C). Crystallisation statistics in  
640 supplementary table 1, 2FoFc map (blue mesh,  $\sigma=1.5$ ), FoFc (Green mesh,  $\sigma=3.0$ ).

641 **Figure 4: HAdV-D26K forms a complex interaction network of hydrophobic and electrostatic**  
642 **interactions with sialic acid.** Sialic acid (orange) is seen to bind HAdV-D26 (A) and HAdV-D37 (B)  
643 through a network of polar contacts (red dashes) and hydrogen bonds (blue dashes). The interaction  
644 is stabilised by hydrophobic interactions (red regions on white surface) with the N-Acetyl  $\text{CH}_3$  group,  
645 but different residues in HAdV-D26 (C) and HAdV-D37 (D). Waters are shown as cyan spheres, residues  
646 forming comparable contacts in HAdV-D26 and HAdV-D37 are shown as blue sticks, other residues are  
647 shown as green sticks. Oxygen and nitrogen are seen in red and blue, respectively.

648 **Figure 5: HAdV-D26K affects an induced fit mechanism in sialic acid binding.** HAdV-D26K residue  
649 Gln348 can occupy multiple conformations, with a greater preference for conformation A (capable of  
650 forming a polar contact with the glycerol arm of sialic acid) at pH8.0 (A) than at pH4.0 (B). Ile324 has  
651 two conformations when HAdV-D26K is unliganded (C, PDB 6FJO). However, upon sialic acid binding  
652 the Ile324 adopts a single confirmation creating a hydrophobic indentation around the N-Acetyl  
653 methyl group bounded by Ile324, Ile310, and the ring of Tyr312 (D).

654 **Supplementary Figure 1: Sialic acid forms a stable interaction with HAdV-D26K at both pH4.0 (PDB**  
655 **6QU6) and pH8.0 (PDB 6QU8).** The omit map at pH4.0 (A) shows density for a small molecule ligand,  
656 which can be best modelled by a sialic acid double conformer (B). The same is true at pH8.0 (C), but  
657 the preferred conformations of the glycerol group are different (D). Crystallisation statistics in  
658 supplementary table 1, 2FoFc map (blue mesh,  $\sigma=1.5$ ), FoFc (Green mesh,  $\sigma=3.0$ ).

659 **Supplementary Figure 2: Structure of sialic acid (N-Acetylneuraminic acid, Neu5Ac) in a biologically**  
660 **relevant conformation.** Viewing the Neu5Ac face on with glycerol and N-Acetyl groups labelled in red  
661 boxes, and the carbons numbered (A). Side on the carboxyl group (red box) is seen in the axial  
662 conformation with the C2 OH group planar to the ring (B).





663 **Supplementary Figure 3: HAdV-D26K forms a similar interaction with sialic acid at both pH4.0 (PDB**  
664 **6QU6) and pH8.0 (PDB 6QU8) through a combination of polar, water-bridge, and hydrophobic**  
665 **interactions.** At pH4.0 sialic acid forms numerous polar contacts to charged side chains in HAdV-D26K  
666 (A), similar contacts are seen at pH8.0 and exhibits a lysine double conformer (B). At pH4.0 sialic acid  
667 forms several water bridges stabilising the interaction of the glycerol group (C), the same bridges are  
668 seen at pH8.0 with the addition of a water-bridge contact on the carboxyl group not seen at pH4.0  
669 (D). A hydrophobic interface is formed around the N-Acetyl methyl group which appears to be similar  
670 and stable at pH4.0 (E) and pH8.0 (F). Polar bonds to residues are shown as red dashes, water-bridge  
671 contacts as blue dashes, and waters as cyan spheres. Sialic acid is shown in orange, polar HAdV-D26K  
672 residues as green sticks, and purely hydrophobic residues as red sticks. The HAdV-D26 surface is shown  
673 in white with hydrophobic regions in red. Oxygen and nitrogen atoms are coloured red and blue,  
674 respectively.

675 **Supplementary Figure 4: Species D adenoviruses conserve known sialic acid binding residues.**  
676 Sequence alignment of species D adenovirus fiber-knob proteins. Known HAdV-D26 and HAdV-  
677 D37/64/19p residues forming contacts with sialic acid are highlighted in black and red respectively.  
678 Homologous residues are coloured similarly to the virus which they share the residue with. HAdV-D8  
679 residues at known sialic acid binding locations which are dissimilar to HAdV-D26/37 are highlighted in  
680 blue, as are homologous residues in other viruses. Names utilise the short nomenclature, all are  
681 human species D adenoviruses. Numbering is for HAdV-D26K.

**Figure 1**

**A**

Fiber-Knob Serotype	Sequence Used (Accession)	Sequence Identity to HAdV-D37	Theoretical $\rho$ I
HAdV-D8	AB448767.1	85.16%	9.03
HAdV-D64	AB448772.1	100.00%	9.14
HAdV-D19p	JQ326209.1	98.90%	8.64
HAdV-D26	EF153474.1	56.76%	6.49
HAdV-D37	AB448776.1	100.00%	9.14



**Figure 2**







Figure 3




Figure 4






Figure 5


A




B




C



D




Supplementary Figure 1




Supplementary Figure 2


A




B



### Supplementary Figure 3



### Supplementary Figure 4



**Table 1.** Data collection and refinement statistics for structures generated in this study

<b>PDB Entry</b>	<b>6QU6</b>	<b>6QU8</b>	<b>6FJO</b>
<b>Data Collection</b>			
Diamond Beamline	I04	I04	I04
Date	25/10/2018	25/10/2018	05/12/2017
Wavelength	0.91587	0.91587	0.9795
<b>Crystal Data</b>			
Crystallisation Conditions	0.1 M MIB, 25 % w/v PEG 1500	0.1 M MIB, 25 % w/v PEG 1500	0.1 M SPG, 25% PEG 1500
pH	4.0	8.0	4.0
$a=b=c$ (Å)	85.73	85.92	85.78
$\alpha=\beta=\gamma$ (°)	90.0	90.0	90.0
Space group	P 2 <sub>1</sub> 3	P 2 <sub>1</sub> 3	P 21 3
Resolution (Å)	1.03 – 49.5	1.19 – 42.96	1.17-85.78
Outer shell	1.03 – 1.06	1.19 – 1.22	1.17-1.23
<i>R</i> -merge (%)	5.3 (125.3)	8.5 (276.1)	6.5 (137.0)
<i>R</i> -meas (%)	5.5 (161.3)	8.8 (283.2)	6.6 (140.4)
CC1/2	1.0 (0.224)	1.0 (0.505)	1.00 (0.825)
<i>I</i> / $\sigma$ ( <i>I</i> )	21.9 (0.7)	20.7 (1.3)	24.8 (2.3)
Completeness (%)	97.7 (76.5)	100.0 (100.0)	100.0 (100.0)
Multiplicity	14.9 (2.0)	21.4 (20.3)	21.8 (21.2)
Total Measurements	1,509,159	1,448,478	1,568,641
Unique Reflections	103,975	67,799	71,878
Wilson B-factor(Å <sup>2</sup> )	8.4	11.1	12.2
<b>Refinement Statistics</b>			
Total number of refined	1,936	1,846	1,761
R-work reflections	96,027	64,286	68,283
R-free reflections	4,907	3,441	3,558
R-work/R-free (%)	13.6 / 14.8	14.17 / 17.20	17.0 / 19.0
<b>rms deviations</b>			
Bond lengths (Å)	0.012	0.011	0.021
Bond Angles (°)	1.754	1.661	2.080
<sup>1</sup> Coordinate error	NULL	NULL	0.026
Mean B value (Å <sup>2</sup> )	17.6	29.6	19.9
<b>Ramachandran Statistics</b>			
Favoured/allowed/Outliers	119 / 9 / 0	126 / 10 / 0	133 / 10 / 1
%	93.0 / 7.0 / 0.0	92.7 / 7.4 / 0.0	92.4 / 6.9 / 0.7

\* One crystal was used for determining each structure.

\* Figures in brackets refer to outer resolution shell, where applicable.

<sup>1</sup> Coordinate Estimated Standard Uncertainty in (Å), calculated based on maximum likelihood statistics.

Buffers:

- MIB: Malonic acid, Imidazole, Boric acid
- SPG: Succinic acid, Sodium phosphate monobasic monohydrate, Glycine: pH 4.0